UNSPSC 51111868: Terguride

This classification denotes a lisuride analog, ergoline, and dopamine agonist with the molecular formula C20H28N4O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 21OJT43Q88, chemically known as 9,10-alpha-dihydrolisuride but generally known as terguride, which bears US NIH Compound Identifier 37816. European Medicines Agency schedules Terguride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10923MIG.

UNSPSC 51111868 Terguride is a Commodity code for a pharmaceutical active ingredient used in migraine and Parkinson's disease treatment. State and local governments procure terguride primarily through institutional healthcare purchasing — most commonly state Medicaid agencies, state health departments, county health systems, and public hospital networks. The drug is typically acquired as part of broader pharmaceutical procurement or specialty medication formulary management, often bundled with other ergot alkaloid derivatives or through group purchasing organization (GPO) agreements that coordinate multi-jurisdiction buying.

The recent-opportunities block contains no active solicitations under this code. State and local procurement activity in pharmaceutical active ingredients at the Commodity level is sparse, as most jurisdictions source these materials through established GPO contracts, state-level preferred-drug lists, or centralized pharmacy benefit managers rather than through open solicitations. When terguride procurement does occur, it routes through existing blanket purchase agreements or state pharmaceutical cooperative purchasing vehicles rather than generating standalone RFPs or ITBs. Absence of posted opportunities under this code does not signal lack of demand — it reflects the consolidated, behind-the-scenes nature of institutional drug procurement in the public sector.